Is CBD a banned substance? What the 2026 WADA list says
No, CBD is not a doping substance. The World Anti-Doping Agency (WADA) took it off its Prohibited List on 1 January 2018, and the 2026 List still names it as an exception. THC remains banned in competition. For an athlete, the risk comes from the traces of THC that a CBD product may contain.
Key takeaways
- Section S8 "Cannabinoids" of the 2026 List names cannabidiol as its one exception and prohibits every other cannabinoid in competition.
- Urine above 150 ng/mL of carboxy-THC, a THC metabolite, makes a test positive, and laboratories apply a decision limit of 180 ng/mL.
- The French 0.30% THC limit governs what may be sold and has no bearing on the result of a urine test.
- Since 2021, use out of competition and unrelated to performance carries a 3-month suspension, cut to 1 month after a treatment programme.
What the 2026 Prohibited List says
The WADA list is an international standard revised every year. France publishes it in the Official Journal, and the version in force since 1 January 2026 is in decree no. 2025-1226 of 15 December 2025. Section S8 prohibits "all natural and synthetic cannabinoids" in competition: cannabis, hashish, natural or synthetic THC, and molecules that mimic THC. Cannabidiol is the single exception.
This dates from 2018. The US Anti-Doping Agency summary states it directly: starting in 2018, cannabidiol is no longer prohibited under the S8 category. It adds a warning that still applies: CBD extracted from the plant may contain varying amounts of THC.
"In competition" has a precise meaning. The ban applies to the competition period, and the test measures what remains in the body on that day, whenever the use took place. As the French Anti-Doping Agency (AFLD) explains, the presence of the substance in the body is what counts, whatever the time of intake. THC is eliminated slowly, so use several days before an event can still be detected in urine.
The 150 ng/mL threshold, and what it really measures
In urine, the laboratory looks for carboxy-THC (THC-COOH), the main metabolite the liver produces as it breaks THC down. A WADA explanatory note on section S8 states that a result above 150 ng/mL is reported as adverse, with a decision limit of 180 ng/mL to allow for measurement uncertainty.
Until 2013 the threshold was 15 ng/mL. WADA multiplied it by ten so that past use with no link to competition would stop being sanctioned. The note quantifies the result: 400 to 500 adverse findings a year from 2009 to 2012, and fewer than 100 in 2021.
Three thresholds come up in discussions of CBD and sport, and each one measures something different:
| Threshold | What it measures | Who applies it |
|---|---|---|
| 0.30% | Δ⁹-THC in the product sold | French law, for placing on the market |
| 150 ng/mL | Carboxy-THC in the athlete's urine | WADA, in competition |
| 50 ng/mL | Urinary carboxy-THC, screening cut-off | Laboratory in the study cited below, outside sport |
Meeting the 0.30% legal limit gives a product no anti-doping guarantee. The outcome depends on the dose of THC actually swallowed or inhaled, on frequency, and on each person's metabolism.
The trap of trace THC in a CBD product
A pure CBD isolate has no THC. A full-spectrum product has some by definition, under the legal ceiling. Our comparison of full spectrum and isolate explains the difference.
A study published in JAMA Psychiatry in 2021 gives an order of magnitude. For four weeks, fourteen adults took a full-spectrum extract supplying about 30 mg of CBD and under 1 mg of THC a day. By the end, 7 of the 14 were positive for carboxy-THC at the laboratory's 50 ng/mL cut-off. The highest concentration, 71.5 ng/mL, stayed under the WADA threshold and above a common screening cut-off. A higher dose, or a product stronger than its label, would narrow the margin.
The French market adds uncertainty of its own. A report published in December 2023 with MILDECA support analysed 248 products bought in France. Of these, 88% contained less than 0.3% THC, while 30 samples showed 0.4 to 1.2%, mostly flowers, resins, pollens and e-liquids. The AFLD warns that some CBD oils or extracts may contain other, prohibited cannabinoids, and says it cannot vouch for what these products contain.
If you are a tested athlete, three points sum up the caution needed. An isolate is less risky than a full-spectrum product. A flower or resin, which always contains some THC and THCA, is riskier. A batch analysis only counts if it covers the batch you bought; our guide to reading a certificate of analysis shows which lines to check.
Sanctions: what changed in 2021
The 2021 World Anti-Doping Code put THC among the "substances of abuse", with cocaine, heroin and MDMA. French law applies this through article L232-23-3-3 of the Sport Code. An athlete who shows that use was out of competition and unrelated to performance receives a three-month suspension. Following a treatment programme approved by the AFLD can reduce it to one month. In every other case the standard sanctions apply.
The American sprinter Sha'Carri Richardson is a case in point. She tested positive for carboxy-THC at the US Olympic Trials on 19 June 2021 and accepted a one-month suspension after completing a counselling programme. Her qualifying result was cancelled, and she missed the 100 m at the Tokyo Games. Cannabis was legal in the state where she was tested, which gave her no protection from a sporting sanction.
At the request of several agencies, a WADA expert group reviewed THC's status in 2022. It concluded that THC meets the criteria for staying on the list, as a health risk, particularly for young people, and as contrary to the spirit of sport. The note acknowledges that the data show no gain in physical performance, and it leaves open a possible effect at the neuropsychological level.
Who is covered, and the case of horses
The rules cover every athlete, amateurs included, who takes part in a competition organised or authorised by a federation that has signed the Code. Testing in France is done by the AFLD. If you never enter an official competition, this regime does not apply to you. THC is still a controlled drug, though, and products remain subject to the 0.30% limit.
Horses have their own list. The 2026 list of the International Equestrian Federation classes cannabidiol among its controlled substances, while WADA allows it for humans. That regime is explained in our article on CBD and competition horses. For human athletes and recovery, our full article on CBD and the anti-doping framework covers the subject.
Frequently asked questions
No. Cannabidiol came off the WADA list on 1 January 2018, and section S8 of the 2026 List names it as an exception. Every other cannabinoid, THC included, is still prohibited in competition.
Yes, if the product contains enough THC. In a 2021 study, 7 of 14 participants tested positive at a 50 ng/mL cut-off after taking a full-spectrum extract with less than 1 mg of THC a day. No one exceeded WADA's 150 ng/mL, and a stronger product would leave a smaller margin.
The 0.30% limit concerns Δ⁹-THC in a product sold in France, and the 150 ng/mL threshold concerns carboxy-THC in the athlete's urine. A legal product can therefore produce a positive test.
No waiting period guarantees a negative test, since elimination depends on the dose, the frequency of use and the individual. WADA advises athletes to avoid cannabis for a number of days before a competition. The known orders of magnitude are in our article on how long CBD stays in the body.
Yes, once they enter a competition organised or authorised by a federation that applies the World Anti-Doping Code. In France the AFLD carries out these tests.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.